Breaking News

Holland Takes 2-0 Lead Over Brazil in World Cup Runner-up Match
Tweet TWEET

The Alzheimer's Disease Drug Market Will Triple by 2022, Driven Largely by the Projected Launch of Eli Lilly's Solanezumab

The Alzheimer's Disease Drug Market Will Triple by 2022, Driven Largely by the
                 Projected Launch of Eli Lilly's Solanezumab

Emerging Disease-Modifying Therapy Solanezumab Will Be Used Predominately in
the Mild Alzheimer's Disease Segment, According to a New Report from Decision
Resources

PR Newswire

BURLINGTON, Mass., Oct. 29, 2013

BURLINGTON, Mass., Oct. 29, 2013 /PRNewswire/ --Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, projects that the market for Alzheimer's disease (AD)
therapies will nearly triple between 2012 and 2022, despite increasing
genericization and few new product launches expected during this time. The key
driver of growth in the AD drug market will be Eli Lilly's anti-beta-amyloid
monoclonal antibody, solanezumab, the first potentially disease-modifying
therapy (DMT) to launch for AD. Solanezumab is anticipated to launch in the
seven major pharmaceutical markets—the United States, France, Germany, Italy,
Spain, the United Kingdom and Japan—beginning in 2018. By 2022, the drug is
forecast to attain sales in excess of $5 billion in these markets.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Alzheimer's Disease finds that more
than 85 percent of solanezumab's projected total use in 2022 will be in the
mild AD market segment (the population in which the drug is currently being
tested), followed by the pre-AD 1-2 years market segment.* Interviewed thought
leaders believe that DMTs will offer the greatest therapeutic benefit in the
earlier stages of the disease; as such, uptake in the moderate and severe AD
segments is likely to be minimal. Furthermore, Decision Resources expects that
reimbursement authorities across the major markets will closely scrutinize the
value of these therapies and impose restrictions that limit the use of such
agents to specific patient subsets, most likely those patients in the mildest
stages of the disease. This scrutiny will stem from emerging DMTs' anticipated
premium pricing and as-yet unproven cost/benefit ratio coupled with the
growing AD patient population.

"AD patients have unique therapeutic needs depending on the disease severity,
many of which are suboptimally met with current medication," said Decision
Resources Senior Business Analyst Georgiana Kuhlmann, S.M. "Late-stage
emerging DMTs are largely focused on slowing cognitive decline, an advance
that will predominately benefit mild AD and pre-AD patients. In the absence of
novel agents that specifically target the later stages of the disease, the
moderate to severe AD population will likely remain underserved throughout the
forecast period."

*Decision Resources defines the pre-AD 1-2 years population as those patients
who will go on to develop overt Alzheimer's disease within the next one to two
years.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Website: http://www.decisionresources.com
Contact: Decision Resources Group, Christopher Comfort, 781-993-2597,
ccomfort@dresources.com